WESTLAKE VILLAGE, Calif. — September 8, 2025 — Leads & Copy — Angitia Biopharmaceuticals announced data from its AGA2115 program for osteogenesis imperfecta (OI) at the American Society for Bone and Mineral Research 2025 Annual Meeting (ASBMR) held Sept. 5-8 in Seattle, WA. The clinical data demonstrated that AGA2115 drove dose-dependent increases in bone mineral density. In addition, the company and collaborators presented data from non-human primate and mouse models.
According to Angitia, AGA2115 is a bispecific antibody targeting both sclerostin and DKK1, which led to increases in bone formation, decreases in bone resorption, and improvements in bone mineral density (BMD) in humans. The company also presented multiple abstracts showcasing data from non-human primates (NHPs) and two mouse models (oim/oim and Brtl/+), which demonstrated improvements in bone density, strength, and organization following treatment with a sclerostin/DKK1 bispecific antibody.
AGA2115 was safe and well-tolerated at all dose levels tested, with adverse events balanced between treatment and placebo. No treatment-related serious adverse events (SAEs) were reported.
In the SAD portion of the trial, at the highest dose, a single SC injection of AGA2115 led to a mean increase of 9% in lumbar spine BMD at 3 months. In the MAD portion of the trial, at the highest dose, three monthly SC injections of AGA2115 led to mean increases of 14.4% in lumbar spine BMD and 3.6% in total hip BMD at 6 months.
William Windham, Solebury Strategic Communications, can be reached at wwindham@soleburystrat.com or 646-378-2946.
Source: Angitia Biopharmaceuticals
